Cyclarity Therapeutics
- Biotech or pharma, therapeutic R&D
Cyclarity Therapeutics develops novel drugs to prevent common age-related diseases such as atherosclerosis, heart attack, and stroke by addressing the root cause - accumulation of arterial plaque. We recently launched our first in human phase 1 clinical trial for our lead drug candidate, UDP-003, in Adelaide, Australia in partnership with the Victorian Heart Hospital and under the supervision of Dr. Stephen Nicholls, the leading expert in blood vessel plaque formation and treatment. We are currently raising funds for our phase 2 clinical trial and are interested in meeting potential investors, as well as making additional connections for potential partnership, licensing, or collaboration.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}